Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

Grafting surface loops containing antibody epitopes of a poorly expressed flu neuraminidase protein onto a high-expressing, stable scaffold improves its production and stability for vaccine ...